Valuation: Kamada Ltd.

Market Cap 1.24B 124B 420M 364M 342M 311M 584M 40.06B 595M 4.01B 1.57B 20.07B 1.58B 1.54B 66.94B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.24B 124B 420M 364M 342M 311M 584M 40.06B 595M 4.01B 1.57B 20.07B 1.58B 1.54B 66.94B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.85x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
1 day+4.31%
1 week-1.01%
Current month-3.24%
1 month+0.94%
3 months-12.16%
6 months-16.46%
Current year-4.78%
1 week 2,013
Extreme 2013
2,198
1 month 2,013
Extreme 2013
2,260
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 57 2015-06-30
Director of Finance/CFO 55 2017-12-30
Chief Operating Officer 53 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Free

Director

30,000 0.0520%
8/5/26 Free

Chairman

30,000 0.0520%
8/5/26 Free

Director

30,000 0.0520%
Change 5-day change 1-year change 3-year change Capi.($)
+4.31%-1.01%-14.94%+13.62% 399M
+1.00%+4.86%+44.81%-0.12% 79.68B
+0.97%+4.90%-0.37%+26.99% 50.61B
-1.22%-4.41%+17.13%+167.13% 48.81B
-0.66%+5.25%-47.97%-48.32% 46.91B
+0.85%+1.95%+63.38%-23.03% 30.86B
-0.03%+13.15%+148.05%-37.28% 25.42B
-0.21%+0.60%+47.68%+82.80% 24.48B
-0.42%+5.37%+8.99%+187.03% 21.2B
-3.14%-0.95%+65.43%+161.38% 16.39B
Average +0.14%+2.51%+33.22%+53.02% 34.48B
Weighted average by Cap. -0.00%+2.90%+29.82%+41.28%

Financials

2026 *2027 *
Net sales 604M 60.44B 204M 177M 166M 151M 284M 19.5B 290M 1.95B 764M 9.77B 767M 751M 32.59B 671M 67.09B 227M 197M 185M 168M 316M 21.65B 322M 2.17B 848M 10.84B 851M 833M 36.17B
Net income 83.3M 8.33B 28.17M 24.44M 22.92M 20.86M 39.2M 2.69B 39.92M 269M 105M 1.35B 106M 103M 4.49B 108M 10.8B 36.51M 31.68M 29.7M 27.04M 50.8M 3.48B 51.74M 349M 136M 1.75B 137M 134M 5.82B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-08-13 ILA 2,152.00 +4.31% 607,781
26-08-12 ILA 2,063.00 -3.15% 668,572
26-08-11 ILA 2,130.00 -0.65% 46,917
26-08-10 ILA 2,144.00 +0.09% 72,155
26-08-07 ILA 2,142.00 +1.52% 23,568
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock